First Eagle Investment Management LLC Purchases 24,999 Shares of Sanofi (NASDAQ:SNY)

First Eagle Investment Management LLC boosted its position in Sanofi (NASDAQ:SNYGet Rating) by 118.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 46,189 shares of the company’s stock after acquiring an additional 24,999 shares during the period. First Eagle Investment Management LLC’s holdings in Sanofi were worth $2,314,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Fisher Asset Management LLC raised its position in shares of Sanofi by 0.4% during the fourth quarter. Fisher Asset Management LLC now owns 17,981,595 shares of the company’s stock worth $900,878,000 after purchasing an additional 75,166 shares during the period. Bank of America Corp DE raised its position in Sanofi by 3.0% in the 4th quarter. Bank of America Corp DE now owns 10,539,487 shares of the company’s stock valued at $528,028,000 after buying an additional 305,627 shares during the last quarter. Boston Partners raised its position in Sanofi by 51.2% in the 4th quarter. Boston Partners now owns 6,943,569 shares of the company’s stock valued at $347,796,000 after buying an additional 2,352,385 shares during the last quarter. Lazard Asset Management LLC raised its position in Sanofi by 2.8% in the 4th quarter. Lazard Asset Management LLC now owns 3,296,264 shares of the company’s stock valued at $165,142,000 after buying an additional 90,994 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its position in Sanofi by 77.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,508,305 shares of the company’s stock valued at $120,925,000 after buying an additional 1,098,676 shares during the last quarter. Institutional investors and hedge funds own 12.82% of the company’s stock.

Shares of NASDAQ SNY traded up $0.81 during trading on Friday, reaching $52.03. The company had a trading volume of 2,022,481 shares, compared to its average volume of 2,197,365. The company’s fifty day moving average price is $52.96 and its 200-day moving average price is $51.49. Sanofi has a 12 month low of $46.92 and a 12 month high of $58.10. The stock has a market cap of $131.49 billion, a P/E ratio of 16.84, a PEG ratio of 1.04 and a beta of 0.50. The company has a quick ratio of 1.03, a current ratio of 1.44 and a debt-to-equity ratio of 0.25.

The business also recently declared an annual dividend, which will be paid on Wednesday, June 8th. Shareholders of record on Thursday, May 5th will be given a $1.7968 dividend. The ex-dividend date is Wednesday, May 4th. This represents a dividend yield of 2.7%. Sanofi’s dividend payout ratio (DPR) is presently 42.07%.

A number of research analysts have weighed in on SNY shares. Barclays raised their price target on Sanofi from €90.00 ($94.74) to €105.00 ($110.53) in a research note on Thursday, April 14th. Liberum Capital upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, January 25th. Guggenheim boosted their price target on Sanofi from €121.00 ($127.37) to €127.00 ($133.68) in a research note on Monday, May 2nd. UBS Group reduced their price target on Sanofi from €122.00 ($128.42) to €121.00 ($127.37) and set a “buy” rating for the company in a research note on Friday, April 8th. Finally, Stifel Nicolaus initiated coverage on Sanofi in a research note on Monday, February 28th. They issued a “buy” rating for the company. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Sanofi presently has a consensus rating of “Buy” and an average price target of $99.86.

Sanofi Company Profile (Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

See Also

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYGet Rating).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.